Donidalorsen

Last updated

Donidalorsen
Donidalorsen.svg
Clinical data
Trade names Dawnzera
Other namesISIS 721744, ISIS-721744
AHFS/Drugs.com Dawnzera
License data
Routes of
administration 		Subcutaneous
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII

Donidalorsen, sold under the brand name Dawnzera, is a medication used to prevent attacks of hereditary angioedema. [1] Donidalorsen is a prekallikrein-directed antisense oligonucleotide. [1] It is given by injection under the skin (subcutaneous). [1]

Contents

Donidalorsen was approved for medical use in the United States in August 2025. [2]

Medical uses

Donidalorsen is indicated for prophylaxis to prevent attacks of hereditary angioedema. [1]

Society and culture

Donidalorsen was approved for medical use in the United States in August 2025. [3]

Names

Donidalorsen is the international nonproprietary name. [4]

Donidalorsen is sold under the brand name Dawnzera. [1]

References

  1. 1 2 3 4 5 6 https://www.ionis.com/medicines/DAWNZERA/DAWNZERA-FPI.pdf
  2. ↑ "Dawnzera (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema" (Press release). Ionis Pharmaceuticals. 21 August 2025. Retrieved 22 August 2025– via Business Wire.
  3. ↑ "Dawnzera: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 22 August 2025.
  4. ↑ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86". WHO Drug Information. 35 (3). hdl: 10665/346562 .

Further reading


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.